Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NaviGate Cardiac Structures has developed and manufactured the GATE™ tricuspid atrioventricular stent (AVS), which has been successfully implanted in patients with severe tricuspid regurgitation. The company also developed the percutaneous NAVI™ mitral valve for minimally invasive treatment of mitral regurgitation. Clinical results include successful first-in-human implantations demonstrating feasibility and safety in high-risk patients [1].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NaviGate Cardiac Structures.